BioCentury
ARTICLE | Clinical News

Aptiom eslicarbazepine acetate regulatory update

November 11, 2013 8:00 AM UTC

FDA approved an NDA from Dainippon's Sunovion Pharmaceuticals Inc. subsidiary for Aptiom eslicarbazepine as an add-on therapy to treat partial-onset seizures in adults with epilepsy. The company plans...